company background image
MVP

Medical Developments InternationalASX:MVP Stock Report

Market Cap

AU$347.1m

7D

-2.8%

1Y

-28.6%

Updated

02 Dec, 2021

Data

Company Financials +
MVP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MVP Stock Overview

Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices.

Price History & Performance

Summary of all time highs, changes and price drops for Medical Developments International
Historical stock prices
Current Share PriceAU$4.94
52 Week HighAU$7.24
52 Week LowAU$3.21
Beta1.21
1 Month Change-2.18%
3 Month Change40.74%
1 Year Change-28.61%
3 Year Change20.78%
5 Year Change16.24%
Change since IPO929.17%

Recent News & Updates

Shareholder Returns

MVPAU PharmaceuticalsAU Market
7D-2.8%-0.4%-2.1%
1Y-28.6%-9.6%10.7%

Return vs Industry: MVP underperformed the Australian Pharmaceuticals industry which returned -8.4% over the past year.

Return vs Market: MVP underperformed the Australian Market which returned 11.7% over the past year.

Price Volatility

Is MVP's price volatile compared to industry and market?
MVP volatility
MVP Average Weekly Movement7.6%
Pharmaceuticals Industry Average Movement8.4%
Market Average Movement8.4%
10% most volatile stocks in AU Market15.7%
10% least volatile stocks in AU Market3.7%

Stable Share Price: MVP is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: MVP's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200368Brent MacGregorhttps://medicaldev.com

Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. The company operates through three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management for use in home or in hospitals; Penthrox, a prescription only medicine for pain in trauma; and medical devices, such as CPR face shield key rings, CPR masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, OXI port carry and hand bags, resuscitation kits, oxygen therapy masks, and resuscitators.

Medical Developments International Fundamentals Summary

How do Medical Developments International's earnings and revenue compare to its market cap?
MVP fundamental statistics
Market CapAU$347.13m
Earnings (TTM)-AU$12.56m
Revenue (TTM)AU$25.27m

13.9x

P/S Ratio

-28.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MVP income statement (TTM)
RevenueAU$25.27m
Cost of RevenueAU$6.17m
Gross ProfitAU$19.10m
ExpensesAU$31.66m
Earnings-AU$12.56m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.18
Gross Margin75.57%
Net Profit Margin-49.72%
Debt/Equity Ratio0%

How did MVP perform over the long term?

See historical performance and comparison

Valuation

Is Medical Developments International undervalued compared to its fair value and its price relative to the market?

5.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: MVP (A$4.87) is trading above our estimate of fair value (A$0.16)

Significantly Below Fair Value: MVP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MVP is unprofitable, so we can't compare its PE Ratio to the Global Pharmaceuticals industry average.

PE vs Market: MVP is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MVP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MVP is overvalued based on its PB Ratio (5.1x) compared to the XX Pharmaceuticals industry average (2.4x).


Future Growth

How is Medical Developments International forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

84.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MVP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: MVP is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MVP's is expected to become profitable in the next 3 years.

Revenue vs Market: MVP's revenue (30.5% per year) is forecast to grow faster than the Australian market (5.2% per year).

High Growth Revenue: MVP's revenue (30.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MVP's Return on Equity is forecast to be low in 3 years time (1.8%).


Past Performance

How has Medical Developments International performed over the past 5 years?

-74.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MVP is currently unprofitable.

Growing Profit Margin: MVP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MVP is unprofitable, and losses have increased over the past 5 years at a rate of 74.2% per year.

Accelerating Growth: Unable to compare MVP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MVP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.4%).


Return on Equity

High ROE: MVP has a negative Return on Equity (-18.4%), as it is currently unprofitable.


Financial Health

How is Medical Developments International's financial position?


Financial Position Analysis

Short Term Liabilities: MVP's short term assets (A$47.4M) exceed its short term liabilities (A$7.0M).

Long Term Liabilities: MVP's short term assets (A$47.4M) exceed its long term liabilities (A$24.9M).


Debt to Equity History and Analysis

Debt Level: MVP is debt free.

Reducing Debt: MVP has no debt compared to 5 years ago when its debt to equity ratio was 2.5%.

Debt Coverage: MVP has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MVP has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Medical Developments International current dividend yield, its reliability and sustainability?

0.20%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MVP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MVP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MVP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MVP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: MVP is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MVP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Brent MacGregor (57 yo)

1.08yrs

Tenure

AU$1,325,143

Compensation

Mr. Brent MacGregor serves as Director at Dynavax Technologies Corporation since July 2020. He has been the Chief Executive Officer of Medical Developments International Limited since November 01, 2020. Mr...


CEO Compensation Analysis

Compensation vs Market: Brent's total compensation ($USD940.22K) is above average for companies of similar size in the Australian market ($USD544.14K).

Compensation vs Earnings: Insufficient data to compare Brent's compensation with company performance.


Leadership Team

Experienced Management: MVP's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: MVP's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MVP insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.6%.


Top Shareholders

Company Information

Medical Developments International Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Medical Developments International Limited
  • Ticker: MVP
  • Exchange: ASX
  • Founded: 2003
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$347.134m
  • Shares outstanding: 71.28m
  • Website: https://medicaldev.com

Number of Employees


Location

  • Medical Developments International Limited
  • 4 Caribbean Drive
  • Scoresby
  • Victoria
  • 3179
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/02 07:05
End of Day Share Price2021/12/02 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.